Terminated NA NCT00145704

Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density

Treatment of Childhood Cancer Therapy-induced Osteopenia in Growth Hormone Deficient Adult Survivors: Does Bisphosphonate Treatment Improve Bone Mineral Density?

Sponsor: Genentech, Inc.

Conditions Osteopenia

Interventions Calcium Vitamin D supplement bisphosphonate therapy (risedronate)

Updated 8 times since 2017 Last updated: Mar 1, 2013 Started: Jun 30, 2002 Primary completion: Oct 31, 2008 Completion: Oct 31, 2008

This NA trial investigates Osteopenia and is currently terminated or withdrawn. Genentech, Inc. leads this study, which shows 8 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated NA
Jul 2024 — Sep 2024 [monthly]

Terminated NA
Jan 2023 — Jul 2024 [monthly]

Terminated NA
Dec 2022 — Jan 2023 [monthly]

Terminated NA
Dec 2021 — Dec 2022 [monthly]

Terminated NA

▶ Show 3 earlier versions

Jan 2021 — Dec 2021 [monthly]

Terminated NA
Jun 2018 — Jan 2021 [monthly]

Terminated NA
Jan 2017 — Jun 2018 [monthly]

Terminated NA

First recorded

Jun 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.
State University of New York - Upstate Medical University

Data source: State University of New York - Upstate Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Syracuse, United States